

2011 BIO International Convention

List of Topics

Disc #	Topic Title	Topic ID
1	Biotechnology Entrepreneurship Boot Camp: Session 1 Opening Remarks and Overview of Program and Session 2 Biotechnology and	24668
	Biotechnology Entrepreneurship Boot Camp: Session 3 Project, Product or Company Assessment and Qualification of Technologies a	24669
	Biotechnology Entrepreneurship Boot Camp: Session 4 Reimbursement and Pricing Strategies	24690
	Biotechnology Entrepreneurship Boot Camp: Session 5 What Every Investigator Must Know about IP in Biotechnology Startups	27050
	Biotechnology Entrepreneurship Boot Camp: Session 6 Regulatory Planning and the Implication for Strategy and Financing	27051
	Biotechnology Entrepreneurship Boot Camp: Session 7 Building an Entrepreneurial Management Team	27052
	Biotechnology Entrepreneurship Boot Camp: Session 8 The Business Plan and Pitch Book in the Fund Raising Process	27053
2	Biotechnology Entrepreneurship Boot Camp: Session 9 Local Company Delivers a Partnering Pitch	27054
	Biotechnology Entrepreneurship Boot Camp: Session 10 Combined Break with Small Group Discussion of Session 8	27055
	Biotechnology Entrepreneurship Boot Camp: Session 11 Licensing,Partnering,Strategic Alliances and University Realtionships	27056
3	Biotechnology Entrepreneurship Boot Camp: Session 12 Capitalization of the Venture	27057
	Biotechnology Entrepreneurship Boot Camp: Session 13 Keynote Address	27058
	Biotechnology Entrepreneurship Boot Camp: Session 14 Local Company to Pitch tp VCs	27059
	Biotechnology Entrepreneurship Boot Camp: Session 15 Combined Break with Small Group Discussion of Session 15	27060
	Biotechnology Entrepreneurship Boot Camp: Session 16 Exit Strategies	27061
4	Biotechnology Entrepreneurship Boot Camp: Session 17 Mock Term Sheet Negotiation	27062
	Leadership Summit: Deploying Agricultural and Industrial Biotechnologies to Meet Development Challenges	24670
	Translational Research Forum: Translational Medicine - A Global Endeavor Part 1	24671
	Drug Patent Linkage and Compulsory Licensing - Challenges of Working Patented Inventions in India for Pharma Sector	24674
	Crossing the Financing Gap? Alternative Strategies for Funding Biomedical Technologies for the Clinic	24678
	Translational Research Forum: Translational Medicine - A Global Endeavor Part 2	27078
	Getting Approval for Drugs in an Ever-Increasing Risk-Averse World	24672
5	Use of Imaging in Clinical Development: Risk Management Strategies for Site and Independent Image Evaluations	24673
	The Effect of a More Risk Averse Environment on Licensing Deals	24675
	Keys to Successful Orphan Drug Development: Three Case Studies	24677
	Vaccines vs. Superbugs! The New Fight Against Hospital-Acquired Infections	24679
	Taiwan: Post ECFA Era-Opportunities for Global Biomedical Market	24680
6	Italy: Research in Space: A New Frontier for Biology and Medicine; The Biomedical Activities of Italian Space Agency (ASI).	24790
	Rare Disease Drug Development Goes Mainstream: What are the Regulatory Considerations?	24682
	IP Issues Affecting Biomarker-Based Diagnostics	24683
	A Brave New World: Patent Litigation Tactics and Strategies for Biosimilars	24684
	Disco Inferno - Pharma Feels the Heat With Discovery Deals	24685
	M&A: Unique Risks and How Insurance Can Help Manage Some of Those Risks	24687
	The Future of the Healthcare Industry: Korean Bio & Pharmaceutical Business Opportunities	26435
7	What Is the Future for Innovative Medicines in Our Industry's Pipeline?	24686
	The Vaccine Business Opportunity - Breakthrough Technologies for Preventing and Treating Disease	24688
	Belgium: Funding Initiatives Boosting Biotech R&D	24689
	Better Living Through Biology - Synthetic Biology for Biofuel and Chemistry Production	24696
	De-risking the Phase II to Phase III Advancement Decision: Sound Science, Critical Thinking and Weighing Time vs. Cost	24701
	Creative Financing for the Next Generation of Blockbuster Biotechnologies	24702
	Belt-Tightening by the States: Impact of Health Reform and Deficit Control on Biotechnology Innovation	24705
8	Brazil: Bringing Innovation to Life through Partnerships with Academia, Industry & Government	24707
	Optimizing the Review Process for Medical Countermeasures Requiring Use of the Animal Rule for Approval/Licensure	24691
	Rediscovering the Promise of Biomarkers	24697
	The Myriad Case and the Patentability of Isolated DNA Molecules	24698
	How Will We Afford Personalized Medicines?	24700
	International Regulation of Animal Biotechnology: A Discussion	24703
	Is the World Ready for the Next Pandemic? A Look at Government and Industry Working Together	24704
9	Patient Compliance and Market Opportunities: The Need for Half-life Extension	24708
	The Partnering Conundrum: To Partner or Not to Partner, That Is the Question . . .	24699
	The Pursuit of Alternative Influenza Vaccines: Where Are We Now, What Challenges Remain?	24706
	Switzerland: Swiss Biotech - Innovative Platforms for Binding Protein Therapeutics	24709
	Addressing the Major Medical Challenges of Today with Personalized Medicine: Cancer,Diabetes and Brain Injury	24715
	Chasing Zero	24722
	'Common Needs' and Uncommon Cooperation: The State of Joint FDA and CMS Initiatives	24724
10	Collocation Strategies for Cellulosic Biofuel Production: Win-Win Scenarios Through Plant Integration	24711
	Patents in the Supreme Court	24713
	Navigating New Trends in the Industry: How Pharma and Biotech Collaborations Are Shaping the Future of Drug Development	24714
	Financing Beyond the Lead Compound: Attracting Funding for Multiproduct Platforms	24721
	Going Global Overnight - Part II: Building Sustainable Investment in Emerging Markets	24723
	Talking About Your Product in the New Age: Social Media and the Internet	24745
	The Biomarkers Consortium: Facilitating the Development and Qualification of Biological Markers	24712
11	The Road to Commercialization: What Role Can the Patient Community Play?	24719
	Therapeutic and Prophylactic Approaches for the Treatment of HSV-2 Infection	24725
	The Biomanufacturing Capacity Conundrum: Matching Supply and Demand Over Space and Time	24726
	Ernst & Young's 25th Annual Biotechnology Industry Report	24727
	Mexico: Commercialization of Biotechnology Research in Mexico	24728
12	How Will Congress Act on Upcoming PDUFA Reauthorization	24729
	Capitol Hill Trumps Wall Street? Finding the Harmony in Biorenewable R&D	24730
	Counterfeiting - How Corporations and the Government Can Work Together	24732
	EU/US Cooperation to Support Research on Rare Diseases	24738
	Current Challenges in Payment System Reform	24739
	Attacking the Next Biomanufacturing Bottleneck: Downstream Processing	24742
	Rare Diseases Experience as a Model to Critically Affect Innovation in Biomarker Strategy and Precision Medicine	24731
13	The Changing BD Environment: Overcoming Our Past to Succeed in the Future	24733
	Personalized Oncology: The Emergence of Personalized Medicine Strategies in Oncology Clinical Development and Deal Making	24734
	NIH's Best Kept Secret: Widely Available Research Resources	24735
	Wait, Our Model Isn't Dead! We Just Need to Evolve	24736
	Looking Beyond Row Crops: What's Next for Agricultural Biotechnology?	24737
Therapeutic Cancer DNA Vaccines: Advances in Technologies, Advances Clinical Success	24740	

2011 BIO International Convention

List of Topics

	Burrill State-of-the-Industry Report	24743
	United Kingdom: Bench, Bed and Beyond: A Vertically-Integrated Approach to Healthcare R&D and Delivery	24744
	Ignoring the Speed Limit: Can New Approaches Truly Affect How Fast Drugs Get to Market?	24751
14	Excellence Through Stewardship (ETS): The value of Quality Management Systems (QMS) to Plant Biotechnology	24753
	Closing the Funding Gap in India for Commercialization of Biotechnology: Moving From Possibility to Opportunity	24754
	From Evidence to Practice: The Impact of Comparative Effectiveness Research on the Physician-Patient Relationship	24755
	Drug Safety for Imported Drug Products	24756
	Navigating the New Law on Licensing Biosimilars	24710
	Markets for Dual-Use Energy Crops	24746
15	The Evolving Business Model for Biomarkers: Status and Future Perspectives	24747
	Is Something Wrong With Our Alliance?: How to Find Out Quickly	24749
	Personalized Medicine and Already Approved Drugs: The Plavix Case Study and What You Don't Know Can Hurt You	24750
	Managing the Capital Agenda Toward a Patient-Centric Future	24752
	It Takes a Village - The Biotechnology Innovation Ecosystem	24757
16	Russia: Launching Innovation: Russia's Bio-Infrastructure and Life Sciences Sector	24758
	A Bittersweet Crossroad? Embarking on the Path to Developing Novel Diabetes Therapies.	24783
	A Look Into the Future of Animal Biotechnology	24785
	Accelerating the Search for Cures: A New Paradigm	26439
	A View from the Hill	24776
	Lessons From a Mature Public-Private Partnership: The Alzheimer's Disease Neuroimaging Initiative	24779
	Technology Transfer: New Methods, New Media, New Models for Improving Interactions with Industry	24780
17	Secrets of the Big Pharma Dealmaker	24781
	Strategic Commercialization for Molecular Diagnostic Tests	24782
	Funding to NDA - New Strategies in Private Financing	24784
	Russian Biopharma: At the Edge of Ambitious 'Pharma2020' Governmental Program	24786
	India: Indian Biotech Industry: Potential Innovator, Collaborator and Partner for Global Health Care	24788
	Spain's R&D Facilities, the Driving Force of an Innovation Ecosystem	24681
	Improving Global Bio-surveillance	24791
	EMA/FDA Town Hall	24792
18	Are Diagnostic Reimbursement Policies Impeding Personalized Medicine?	24797
	Getting a Biotech Crop to Market - How Much, How Long, and What Steps?	24800
	From 'Made in China' to 'Discovered in China' - Challenges and Opportunities	24801
	Whats Happened and Whats to Come in the 112th Congress	26167
	The Next Frontier: Adult Immunizations and Healthcare Reform	26537
	Progress of Research in Bioenergy Centers: An Update on the Major DOE and Other Bioenergy Research Centers	24793
	The Role of Imaging Biomarkers in Early Clinical Phase CNS Drug Development	24794
19	Lessons From In-Licensing Partnership: Biotech Company Partners With Global Pharma to Deliver Cutting-Edge Biosimilars	24795
	Premature or Prescient? When Big Pharma Is Doing Preclinical Deals With Seemingly Clinical-Stage Valuations	24796
	Starting Up Biotechs in the New Normal World	24799
	Looking to the Future: Innovative Approaches to HIV Vaccine Development and Immunotherapies	24803
	The Growing Personal Liability Threat to Bio Executives: The Government is Watching You	26538
	Emerging Markets: The Future of Growth for Biologics?	24804
	FDA - Town Hall	24806
	Managing Global Challenges in an Evolving Threat Environment	24809
20	Collaborative R&D From the Perspective of Large Multinationals, Universities and Start-ups	24810
	IP Challenges for Personalized Medicine: Navigating Bilski, Myriad, and Prometheus	24812
	Collaborations and Strategies to Crossing the Valley of Death to Fund Innovative Medicines	24814
	Saudi Arabia: Medical Biotech: Global Competitiveness of Saudi Arabia	24818
	Countering Counterfeiting	24819
	Stratified Medicine - Hype or Hope	24808
21	Moving to the Next Level: Accessing Capital Internationally	24811
	The Promise of MicroRNA-Based Therapeutics in Cancer	24813
	Views From the Top: Executive Perspectives on Key Policy Issues Facing the Biopharmaceutical Industry	24817
	Campbell Alliance 2011 Dealmakers' Intentions	24820
	The Trans-Pacific Partnership and the Importance of Intellectual Property Rights: Attracting Investment in Biotechnology	26541
	Israel: Creating Biomedical Innovation in Israel: Reciprocal Relationship of University, Industry and Government	24821
	Successes and Challenges in Public-Private Partnerships	24822
	Worldview 2011: Scientific American's Regional Bio-Innovation Scorecard	24823
22	France: Vaccine Innovation, a Collaborative Approach: from Diagnosis to Prevention and Treatment	24824
	Financing Biodefense as a National Security Priority	24825
	Accelerating Product Development With Nondilutive Funding for Private Biotechs	24829
	After the Fall: Venture Capital and the Biotech Funding Landscape	24832
	Experimental Field Trials With Biotech Corn and Conservation of Corn Landraces in Mexico	24833
	European Innovation Union: Fostering Innovations in the Life Sciences	24835
	Biologics & Biosimilars: What is the Science Telling Us?	26169
	White Biotechnology: From Laboratory to Demonstration Scale	24827
	Innovative Collaborations: Deal Structures for Nonprofit/For-Profit Collaborations	24828
	Personalized Medicine and Companion Diagnostics: The Changing Biopharma Industry Landscape	24830
23	Scientific and Regulatory Implications of Changes to ICH S6 for Design and Conduct of Nonclinical Safety Evaluation Programs for Bi	24831
	Improving Innovation Through the use of Social Networks	24834
	Safer, Faster, Cheaper: Changing Process Paradigms, Platforms and Products in Biomanufacturing	24836
	Japan: Japan's Regulatory Reform and Open Innovation Policy: Assisting Global Development of Innovative Drugs	24837
	Protecting the Unprotected: Countermeasures for At-Risk and Vulnerable Populations	24838
	Environmental Review of GE Food and Agriculture Products	24843
	Advanced Molecular Diagnostics: Reforming Regulation and Reimbursement	24844
	Regulatory Issues for Tissue Engineered Products	24839
	Relationship Management: An Essential Key Enabler for Alliance Success	24841
	Success in the States: A Guide for Foreign Companies to the Largest Venture Capital Pool in the World	24842
24	How Dare They Dope With Our Medicines?	24846
	Managing Technological Innovation in the New Era	24848
	The Role of the BWC in a Biotech-Driven World	24849
	European Patent and Unitary EU patent: The Changes Ahead	26174